Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, Laribi de Materre I, Roussel X, Nudel M, Tricot S, Dupuis J, Le Calloch R, Bareau B, Leblond V. Laribi K, et al. Among authors: leblond v. Br J Haematol. 2024 Jun;204(6):2233-2236. doi: 10.1111/bjh.19409. Epub 2024 Mar 19. Br J Haematol. 2024. PMID: 38504454
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Dartigeas C, Quinquenel A, Ysebaert L, Dilhuydy MS, Anglaret B, Slama B, Le Du K, Tardy S, Tchernonog E, Orfeuvre H, Voillat L, Guidez S, Malfuson JV, Dupuis S, Deslandes M, Feugier P, Leblond V; FIRE Investigators Group. Dartigeas C, et al. Among authors: leblond v. Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666-3. Online ahead of print. Ann Hematol. 2024. PMID: 38443660
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
Nguyen-Khac F, Baron M, Guièze R, Feugier P, Fayault A, Raynaud S, Troussard X, Droin N, Damm F, Smagghe L, Susin S, Leblond V, Dartigeas C, Van den Neste E, Leprêtre S, Bernard OA, Roos-Weil D; on behalf the FILO (French Innovative Leukaemia Organization) Group. Nguyen-Khac F, et al. Among authors: leblond v. Br J Haematol. 2024 Aug;205(2):495-502. doi: 10.1111/bjh.19459. Epub 2024 Apr 23. Br J Haematol. 2024. PMID: 38654616
Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.
Baron M, Labreche K, Veyri M, Désiré N, Bouzidi A, Seck-Thiam F, Charlotte F, Rousseau A, Morin V, Nakid-Cordero C, Abbar B, Picca A, Le Cann M, Balegroune N, Gauthier N, Theodorou I, Touat M, Morel V, Bielle F, Samri A, Alentorn A, Sanson M, Roos-Weil D, Haioun C, Poullot E, De Septenville AL, Davi F, Guihot A, Boelle PY, Leblond V, Coulet F, Spano JP, Choquet S, Autran B. Baron M, et al. Among authors: leblond v. Haematologica. 2024 Nov 1;109(11):3615-3630. doi: 10.3324/haematol.2023.284332. Haematologica. 2024. PMID: 38841782 Free PMC article.
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group. Michot JM, et al. Among authors: leblond v. Am J Hematol. 2015 Mar;90(3):197-203. doi: 10.1002/ajh.23889. Epub 2014 Nov 24. Am J Hematol. 2015. PMID: 25417909 Free article. Clinical Trial.
Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.
Ysebaert L, Ederhy S, Leblond V, Malartre S, Portalier A, Sibaud V, Tomowiak C, Zerbit J; Delphi Acalabrutinib Safety Study Group. Ysebaert L, et al. Among authors: leblond v. Clin Lymphoma Myeloma Leuk. 2024 Oct 24:S2152-2650(24)02398-X. doi: 10.1016/j.clml.2024.10.013. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39547859 Review.
Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia.
Heyman BM, Opat SS, Wahlin BE, Dimopoulos MAA, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen AC, Matous JV. Heyman BM, et al. Among authors: leblond v. Blood Adv. 2024 Dec 3:bloodadvances.2024014115. doi: 10.1182/bloodadvances.2024014115. Online ahead of print. Blood Adv. 2024. PMID: 39626287
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Raj K, Eikema DJ, Lawless S, Koster L, Kunadt D, Kröger N, Platzbecker U, Stelljes M, Bethge W, Holderried T, Fanin R, Zeiser R, Kuball J, Leblond V, Nicholson E, Passweg J, Potter V, Bay JO, Bazarbachi A, Corral LL, Gurnari C, Scheid C, Drozd-Sokolowska J, Morris TC, Hayden P, Yakoub-Agha I, Robin M, McLornan DP. Raj K, et al. Among authors: leblond v. Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02462-5. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39533014
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V; on the behalf of the FILO group. Tomowiak C, et al. Among authors: leblond v. Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06076-1. Online ahead of print. Ann Hematol. 2024. PMID: 39499299
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Tedeschi A, Tam CS, Owen RG, Buske C, Leblond V, Dimopoulos M, Garcia-Sanz R, Castillo JJ, Trotman J, Treon SP, Yang K, Tang B, Allewelt H, Patel S, Chan WY, Cohen A, Chen S, Barnes G. Tedeschi A, et al. Among authors: leblond v. Future Oncol. 2024;20(25):1789-1798. doi: 10.1080/14796694.2024.2355079. Epub 2024 Jul 29. Future Oncol. 2024. PMID: 39072392 Free PMC article. Clinical Trial.
416 results